Benevento Ilaria, De Felice Francesca, Musio Daniela, Tombolini Vincenzo
Department of Radiotherapy, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Chemotherapy. 2017;62(5):314-322. doi: 10.1159/000476056. Epub 2017 Jun 9.
Currently, neoadjuvant fluoropyrimidine-based chemoradiotherapy (CRT) is standard practice in the management of locally advanced rectal cancer (LARC). In the last decade there has been a lively interest in the improvement of clinical outcomes by modifying this standard regimen by the addition of further agents. We review combinations of targeted therapies and conventional CRT currently under investigation in LARC patients.
目前，基于氟嘧啶的新辅助放化疗（CRT）是局部晚期直肠癌（LARC）治疗的标准做法。在过去十年中，人们对通过添加其他药物来改进这一标准方案以改善临床结果产生了浓厚兴趣。我们综述了目前正在LARC患者中研究的靶向治疗与传统CRT的联合应用。
